Comments on: Celgene- Take the Money and Run http://www.hammerstockblog.com/celgene-take-the-money-and-run/ Biotech stock reviews Fri, 10 Sep 2010 09:47:48 +0000 http://wordpress.org/?v=2.3.1 By: Ohad Hammer http://www.hammerstockblog.com/celgene-take-the-money-and-run/#comment-607 Ohad Hammer Wed, 01 Apr 2009 07:47:55 +0000 http://www.hammerstockblog.com/celgene-take-the-money-and-run/#comment-607 Hi Eric The CELG news is disappointing, no doubt,but it doesn't justify market reaction, especially given the YE09 guidance. I tought CELG is a good buy at 42$ and I still believe it is at a pps of 40$. There should be plenty of growth beyond 2009 in the Revlimid franchise, particularly fueled by approval in Japan and FDA approval for first line and/or maintenance therapy. Ohad Hi Eric

The CELG news is disappointing, no doubt,but it doesn’t justify market reaction, especially given the YE09 guidance. I tought CELG is a good buy at 42$ and I still believe it is at a pps of 40$. There should be plenty of growth beyond 2009 in the Revlimid franchise, particularly fueled by approval in Japan and FDA approval for first line and/or maintenance therapy.

Ohad

]]> By: eric manes http://www.hammerstockblog.com/celgene-take-the-money-and-run/#comment-606 eric manes Wed, 01 Apr 2009 04:49:02 +0000 http://www.hammerstockblog.com/celgene-take-the-money-and-run/#comment-606 Hi Ohad - I have been enjoying and learning from your posts for many months and have taken positions in several stocks including sgen and exel. What do you think of the earnings news about celg this evening? Seems to me like they essentially confirmed guidance, though at the lower end. The stock is down some 11% after hours and looking like an even more screaming buy at 40. Do you agree? Thanks very much for your insight. Eric Hi Ohad - I have been enjoying and learning from your posts for many months and have taken positions in several stocks including sgen and exel. What do you think of the earnings news about celg this evening? Seems to me like they essentially confirmed guidance, though at the lower end. The stock is down some 11% after hours and looking like an even more screaming buy at 40. Do you agree? Thanks very much for your insight. Eric

]]> By: Ohad Hammer http://www.hammerstockblog.com/celgene-take-the-money-and-run/#comment-589 Ohad Hammer Fri, 13 Mar 2009 22:09:39 +0000 http://www.hammerstockblog.com/celgene-take-the-money-and-run/#comment-589 Thanks, Manish. I think this is a great development for MITI, which will be able to get substantially better terms for 103 after initial proof of concept. I don't think Medimmune know something we don't, it's probably part of AZN's policy, similar to the case of INFI's hsp90 inhibitor and Abraxis' Abraxane. Can't understand these decisions but I can't complain... You rightly mentioned XL184, which was dumped by GSK, picked by BMS for over $100M and is now on the fast track to approval for glioblastoma multiforme. Same thing with DNA and SGN-40. Best, Ohad Thanks, Manish.

I think this is a great development for MITI, which will be able to get substantially better terms for 103 after initial proof of concept. I don’t think Medimmune know something we don’t, it’s probably part of AZN’s policy, similar to the case of INFI’s hsp90 inhibitor and Abraxis’ Abraxane. Can’t understand these decisions but I can’t complain…
You rightly mentioned XL184, which was dumped by GSK, picked by BMS for over $100M and is now on the fast track to approval for glioblastoma multiforme.
Same thing with DNA and SGN-40.

Best,
Ohad

]]> By: Manish http://www.hammerstockblog.com/celgene-take-the-money-and-run/#comment-588 Manish Fri, 13 Mar 2009 03:50:19 +0000 http://www.hammerstockblog.com/celgene-take-the-money-and-run/#comment-588 Ha, followed you on this one too, and sold for a profit today. Very nice call. What do you make of AZN/MedImmune's announcement to give up its licensing rights on MT-103. I am really surprised about this given the fantastic outcome on the phase-1 NHL and phase-2 ALL results. Any idea why they would do this. I remember an earlier post on GSK doing the same with EXEL. I would like to hear your opinion. As always, I appreciate your columns. - Manish Ha, followed you on this one too, and sold for a profit today. Very nice call. What do you make of AZN/MedImmune’s announcement to give up its licensing rights on MT-103. I am really surprised about this given the fantastic outcome on the phase-1 NHL and phase-2 ALL results. Any idea why they would do this. I remember an earlier post on GSK doing the same with EXEL. I would like to hear your opinion. As always, I appreciate your columns.
- Manish

]]>